Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 177,932
  • Shares Outstanding, K 125,304
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,090 K
  • 60-Month Beta 1.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.12
Trade ATOS with:

Options Overview Details

View History
  • Implied Volatility 154.88% ( +13.63%)
  • Historical Volatility 119.24%
  • IV Percentile 79%
  • IV Rank 13.75%
  • IV High 923.44% on 05/01/23
  • IV Low 32.38% on 11/30/23
  • Put/Call Vol Ratio 0.18
  • Today's Volume 164
  • Volume Avg (30-Day) 2,471
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 42,753
  • Open Int (30-Day) 36,088

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2400 +9.68%
on 04/18/24
2.3100 -41.13%
on 04/05/24
-0.1900 (-12.26%)
since 03/19/24
3-Month
0.7744 +75.62%
on 01/25/24
2.3100 -41.13%
on 04/05/24
+0.5400 (+65.85%)
since 01/19/24
52-Week
0.5901 +130.47%
on 04/27/23
2.3100 -41.13%
on 04/05/24
+0.6154 (+82.65%)
since 04/19/23

Most Recent Stories

More News
Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later

/PRNewswire/ -- Physician-Scientist Dr. Steven Quay, MD, PhD is calling for nutritional guidelines for adolescent girls to reduce processed and fast-food...

ATOS : 1.3350 (-5.99%)
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

/PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant...

ATOS : 1.3350 (-5.99%)
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial

/PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant...

ATOS : 1.3350 (-5.99%)
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop...

ATOS : 1.3350 (-5.99%)
Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

Atossa Plans to Initiate a New Development Path in Patients with Compromised Lung-Function Resulting from Cancer Treatment...

ATOS : 1.3350 (-5.99%)
Atossa: Acquiring CAR-T Company Would Be a Great Move, Says Analyst

According to a recent 8-K filed by Atossa Therapeutics (ATOS), the biotech has signed a letter agreement with a private, venture-backed American company. One which is creating CAR-T medicines which have...

ATOS : 1.3350 (-5.99%)
Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations

SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop...

ATOS : 1.3350 (-5.99%)
Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference

SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop...

ATOS : 1.3350 (-5.99%)
Atossa Therapeutics to Present at the Q2 Investor Summit Conference

SEATTLE, April 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop...

ATOS : 1.3350 (-5.99%)
Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION...

ATOS : 1.3350 (-5.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

3rd Resistance Point 1.7600
2nd Resistance Point 1.6200
1st Resistance Point 1.5200
Last Price 1.3350
1st Support Level 1.2800
2nd Support Level 1.1400
3rd Support Level 1.0400

See More

52-Week High 2.3100
Fibonacci 61.8% 1.6530
Fibonacci 50% 1.4500
Last Price 1.3350
Fibonacci 38.2% 1.2471
52-Week Low 0.5901

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar